Novavax, Inc. (BMV:NVAX)
Mexico flag Mexico · Delayed Price · Currency is MXN
124.00
-2.00 (-1.59%)
At close: Aug 1, 2025, 2:00 PM CST

Novavax Company Description

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.

The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.
CountryUnited States
Founded1987
IndustryBiological Products, Except Diagnostic Substances
Employees952
CEOJohn Jacobs

Contact Details

Address:
700 Quince Orchard Road
Gaithersburg, Delaware 20878
United States
Phone240 268 2000
Websitenovavax.com

Stock Details

Ticker SymbolNVAX
ExchangeMexican Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
SIC Code2836

Key Executives

NamePosition
John JacobsChief Executive Officer
James KellyChief Financial Officer
Richard CrowleyChief Operating Officer